NCT06524843 Fracture Risk Evaluation of Bone Metastases Derived From Carcinoma
| NCT ID | NCT06524843 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Costantino Errani |
| Condition | Bone Metastases |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2024-09-23 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2024-09-23 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
From the archives of the Rizzoli institute all patients (approximately 750) treated for bone metastases from 01/01/2010 to 31/12/2022. A review will be made from the medical records, radiological imaging, and histological data of these patients
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of bone metastasis from carcinoma, regardless of the type of carcinoma, and of the number and location of the metastases * Availability of imaging and clinical data * Availability of at least one follow-up during the last 12 months form diagnosis Exclusion Criteria: * At least one inclusion creteria not met
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06524843 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bone Metastases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06524843 currently recruiting?
Yes, NCT06524843 is actively recruiting participants. Contact the research team at costantino.errani@ior.it for enrollment information.
Where is the NCT06524843 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06524843 clinical trial?
NCT06524843 is sponsored by Costantino Errani. The trial plans to enroll 250 participants.